Ayuda
Ir al contenido

Dialnet


TRIM27 suppresses inflammation injuries in pediatric pneumonia by targeting TLR4/NF-κκB signaling pathway

  • Shan Wang [1] ; Baoxia Lu [1] ; Jia Liu [1] ; Yanhong Gu [2]
    1. [1] Anhui Medical University

      Anhui Medical University

      China

    2. [2] The People’s Hospital of Yubei District of Chongqing City, Chongqing, China
  • Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 50, Nº. 2, 2022, págs. 33-39
  • Idioma: inglés
  • Enlaces
  • Resumen
    • Background: Pneumonia widely occurs in children and has high global morbidity and mortality. There is an urgent requirement to clarify the underlying mechanism of pediatric pneumonia and definite its potential therapeutic targets. Tridomain protein 27 (TRIM27) is one of the TRIM protein family members which widely participated in multiple cellular processes. Objective: To assess whether TRIM27 protects against pediatric pneumonia.

      Methods: A lipopolysaccharide (LPS)-induced inflammation injury model was constructed. The level of TRIM27 in LPS-induced cells was examined. The effects of TRIM27 in cell apoptosis and inflammatory response was evaluated. Moreover, the involvement of TLR4/NF-κB pathway were detected by Immunoblot.

      Results: We established a lipopolysaccharide (LPS)-induced inflammation injury model. Our data confirmed that LPS-treated WI-38 cells demonstrated a down-regulated expression of TRIM27. Overexpression of TRIM27 effectively reduced apoptosis and up-regulated the inflammatory factors in LPS-treated WI-38 cells. Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) pathway acted as a key point in LPS-mediated inflammation injuries, and overex-pression of TRIM27 remarkably inhibited the activity of TLR4/NF-κB pathway, indicating the anti-inflammatory effect of TRIM27.

      Conclusion: In conclusion, TRIM27 protects WI-38 cells against LPS-induced inflammation injuries by inhibiting TLR4/NF-κB pathway.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno